Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Sichuan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07376499CT.gov Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | — | Not Yet Recruiting | — | — | — |
NCT07141771CT.gov An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | — | Not Yet Recruiting | — | — | — |
NCT07155200CT.gov Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | — | Recruiting | — | — | — |
NCT06954246CT.gov A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07004712CT.gov Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06951841CT.gov Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction | — | Not Yet Recruiting | — | — | — |
NCT06820762CT.gov Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study | — | Not Yet Recruiting | — | — | — |
NCT06739928CT.gov Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC | — | Recruiting | — | — | — |
NCT06749691CT.gov Liposomal Irinotecan and Apatinib in ES-SCLC | — | Recruiting | — | — | — |
NCT06496048CT.gov Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | — | Recruiting | — | — | — |
Show 41 more trialsShow fewer
NCT06478043CT.gov A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC | — | Not Yet Recruiting | — | — | — |
NCT06462105CT.gov Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06258642CT.gov Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC | — | Recruiting | — | — | — |
NCT06332950CT.gov Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy | — | Not Yet Recruiting | — | — | — |
NCT06467786CT.gov Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06128837CT.gov Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06131840CT.gov A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05049863CT.gov Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial) | — | Terminated | — | — | — |
NCT05731518CT.gov SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | — | Unknown | — | — | — |
NCT05800587CT.gov Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | — | Recruiting | — | — | — |
NCT05595889CT.gov Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05153239CT.gov Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | — | Completed | — | — | — |
NCT04514497CT.gov Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05027100CT.gov Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC | — | Unknown | — | — | — |
NCT04543916CT.gov Venetoclax and Irinotecan in Relapsed/Refractory SCLC | — | Withdrawn | — | — | — |
NCT04727853CT.gov Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) | — | Completed | — | — | — |
NCT04381910CT.gov Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04730999CT.gov Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT04453930CT.gov A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | — | Unknown | — | — | — |
NCT04173325CT.gov Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04757779CT.gov A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer | — | Unknown | — | — | — |
NCT03879798CT.gov DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03651219CT.gov Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03613753CT.gov Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03088813CT.gov Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03098030CT.gov Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02595931CT.gov M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02611024CT.gov Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | — | Completed | — | — | — |
NCT02734004CT.gov A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | — | Active Not Recruiting | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT01941316CT.gov Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT01441349CT.gov Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02323737CT.gov Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00856830CT.gov Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00546130CT.gov Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00057837CT.gov Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00144989CT.gov A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC | — | Completed | — | — | — |
NCT00143455CT.gov Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00031681CT.gov 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | — | Completed | — | — | — |
NCT00168896CT.gov A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Sichuan University | Approved | BB · 70 |
| Benmelstobart | Yayi He | P4 | A |
| Berzosertib | National Cancer Institute (NCI) | P2 | BBB |
| Anti-Pd-L1 Monoclonal Antibody Shr-1316 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Etoposide | Sichuan University | P4 | BBB |
| Carboplatin | University of Maryland, Baltimore | P4 | BB |
| Veliparib | Central European Society for Anticancer Drug Research | P2 | BB |
| Nogitecan | AbbVie | P4 | BB |
+42 more in the Small Cell Lung Carcinoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →